Hemophilia Market Size Share Trends 2023-2030

Hemophilia Market Overview:
The global hemophilia market, which was valued at USD 11.7 billion in 2022, is expected to develop at a profitable rate and might reach USD 18 billion by 2030. It is anticipated that the hemophilia market would grow at a 5.9% CAGR from 2023 to 2030. A hereditary shortage of a coagulation factor causes hemophilia, which is characterized by insufficient blood-clotting proteins and delayed blood clotting.

Typically, medications, replacement therapy, and injections of plasma or clotting factor are used to treat hemophilia. Treatment for hemophilia focuses on substituting missing proteins and avoiding complexities.

Download Sample: https://www.datamintelligence.com/download-sample/hemophilia-market

Market Dynamics:
Throughout the projected years, the major market players' escalating research endeavors will propel the expansion of the worldwide hemophilia market. For example, at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in February 2022, BioMarin Pharmaceutical, a leader in the world of developing and producing cutting-edge biopharmaceuticals for uncommon conditions brought on by genetics, presented positive results from a two-year investigation of the Phase III GENEr8-1 analysis and an all-around safety update of valoctocogene roxaparvovec, an investigational gene therapy for the therapy of adults with extreme hemophilia A.

Market Segment Analysis:
Hemophilia A is predicted to account for around 48.2% of the global hemophilia treatment market by 2030 due to its high prevalence and growing industry trends. For example, the NIH states that 80% of hemophilia patients have hemophilia A, the most common genetic hemostasis disorder that affects one in 5000 men.

Over 400000 boys worldwide have hemophilia A, with the majority going misdiagnosed in underdeveloped countries. Furthermore, in 2022, the Japanese multinational pharmaceutical company Takeda Pharmaceutical Company Limited launched Adynovate, a recombinant Factor VIII (rFVIII) medication with an extended half-life intended for patients with hemophilia A in India.

Hemophilia Market Players:
The major global players in the market include Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion S.p.A, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), and Takeda Pharmaceutical (Shire Plc.), Grifols among others.

Key Developments
In July 2022, EMA instructed awarding a conditional commercializing license in the European Union (EU) for Roctavian (valoctocogene roxaparvovec) for the therapy of extreme hemophilia A in adults who lack factor VIII inhibitors (auto-antibodies elicited by the immune system making factor VIII medicines less useful) and no antibodies to adeno-associated virus serotype 5 (AAV5).

In February 2023, the U.S. Food and Drug Administration (FDA) authorized Sanofi's ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement treatment and is meant for periodic prophylaxis and on-demand therapy to arrest bleeding attacks, and as perioperative management (surgery) for adults and children with hemophilia A.

In March 2022, Freeline Therapeutics Holdings, a foremost biotechnology corporation concentrated on innovative liver-directed gene treatments for bleeding conditions and additional debilitating, chronic diseases, dosed the first patient in its Phase I/II B-LIEVE dose-confirmation clinical investigation of FLT180a for the therapy of hemophilia B, a debilitating genetic bleeding disease induced by a lack in the clotting factor IX protein.

Know More: https://www.datamintelligence.com/research-report/hemophilia-market

Related Reports:

Lyme Disease Diagnostics Market: https://www.datamintelligence.com/research-report/lyme-disease-diagnostics-market

Predictive Diagnostics Market: https://www.datamintelligence.com/research-report/predictive-diagnostics-market

Rapid Medical Diagnostics Market: https://www.datamintelligence.com/research-report/rapid-medical-diagnostics-market

Tissue Diagnostics Market: https://www.datamintelligence.com/research-report/tissue-diagnostics-market

Veterinary Diagnostics Market: https://www.datamintelligence.com/research-report/veterinary-diagnostics-market

Malaria Diagnostics Market: https://www.datamintelligence.com/research-report/malaria-diagnostics-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.